- Home
- PENN vs PVLA Comparison
PENN vs PVLA Comparison
Compare PENN & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PENN | PVLA |
|---|---|---|
| Founded | 1972 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 1.9B |
| IPO Year | 1996 | 2013 |
Fundamental Metrics
Financial Performance| Metric | PENN | PVLA |
|---|---|---|
| Price | $14.42 | $125.01 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 20 | 16 |
| Target Price | $24.13 | ★ $231.25 |
| AVG Volume (30 Days) | ★ 2.8M | 194.5K |
| Earning Date | 11-05-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 52.62 |
| EPS | ★ 0.23 | N/A |
| Revenue | ★ $6,362,900,000.00 | $42,810,000.00 |
| Revenue This Year | $6.65 | N/A |
| Revenue Next Year | $4.26 | N/A |
| P/E Ratio | $67.20 | ★ N/A |
| Revenue Growth | N/A | ★ 65.28 |
| 52 Week Low | $11.65 | $68.96 |
| 52 Week High | $22.36 | $161.38 |
Technical Indicators
Market Signals| Indicator | PENN | PVLA |
|---|---|---|
| Relative Strength Index (RSI) | 38.19 | 40.41 |
| Support Level | $13.86 | $119.42 |
| Resistance Level | $14.99 | $136.35 |
| Average True Range (ATR) | 0.54 | 6.96 |
| MACD | 0.06 | 0.11 |
| Stochastic Oscillator | 3.24 | 33.19 |
Price Performance
Historical ComparisonAbout PENN PENN Entertainment Inc.
Penn Entertainment's origins date back to its 1972 racetrack opening in Pennsylvania. Today, Penn operates 42 properties across 20 states and 12 brands, including Hollywood Casino and Ameristar. Land-based casinos represented 81% of total sales in 2025; 19% was from the interactive segment, which includes sports, i-gaming, and media revenue. The retail portfolio generates low-30s EBITDAR margins and helps position the company to obtain licenses for the digital wagering markets. Additionally, Penn's media asset, theScore, provides access to sports betting/i-gaming technology and clientele, helping it form a leading digital position.
About PVLA Palvella Therapeutics Inc.
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.